Management of patients with pancreatic adenocarcinoma: National trends in patient selection, operative management, and use of adjuvant therapy

Journal of the American College of Surgeons

Volumn 214, Issue 1, 2012, Pages 33-45

  Mayo, Skye C ^a   Gilson, Marta M ^a   Herman, Joseph M ^b   Cameron, John L ^a   Nathan, Hari ^a   Edil, Barish H ^a   Choti, Michael A ^a   Schulick, Richard D ^a   Wolfgang, Christopher L ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HISTOLOGY; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATICODUODENECTOMY; PATIENT CODING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REOPERATION; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS; PATIENT SELECTION; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84355162899     PISSN: 10727515     EISSN: 18791190     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2011.09.022     Document Type: Article

References (33)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. T.A. Sohn, C.J. Yeo, J.L. Cameron Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 2000 567 579
3. M. Fischer, K. Matsuo, M. Gonen Relationship between intraoperative fluid administration and perioperative outcome after pancreaticoduodenectomy: results of a prospective randomized trial of acute normovolemic hemodilution compared with standard intraoperative management Ann Surg 252 2010 952 958
4. National Comprehensive Cancer Network The NCCN Clinical Practice Guidelines in Oncology Pancreatic Adenocarcinoma Version 2.2011 www.NCCN.org Accessed May 21, 2011
5. J.A. Davila, E.Y. Chiao, J.C. Hasche Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer Pancreas 38 2009 e18 e25
6. L. Hazard, J.D. Tward, A. Szabo Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data Cancer 110 2007 2191 2201 (Pubitemid 350100740)
7. M.B. Slidell, D.C. Chang, J.L. Cameron Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis Ann Surg Oncol 15 2008 165 174
8. S.C. Mayo, D.F. Austin, B.C. Sheppard Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis Cancer 116 2010 2932 2940
9. J.P. Neoptolemos, D.D. Stocken, H. Friess A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 2004 1200 1210 (Pubitemid 38339364)
10. H. Oettle, S. Post, P. Neuhaus Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 2007 267 277 (Pubitemid 46143304)
11. W.F. Regine, K.A. Winter, R.A. Abrams Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial JAMA 299 2008 1019 1026 (Pubitemid 351347058)
12. M.J. Horner, L.A.G. Ries, M. Krapcho et al. SEER Cancer Statistics Review 19752006 National Cancer Institute Bethesda, MD http://seer.cancer.gov/csr/ 1975-2006/ based on November 2008 SEER data submission, posted to the SEER Web site, 2009. Accessed November 2010
13. J.L. Warren, L.C. Harlan, A. Fahey Utility of the SEER-Medicare data to identify chemotherapy use Med Care 40 Suppl 2002 IV-55 IV-61
14. B.A. Virnig, J.L. Warren, G.S. Cooper Studying radiation therapy using SEER-Medicare-linked data Med Care 40 Suppl 2002 IV-49 IV-54
15. G.S. Cooper, B. Virnig, C.N. Klabunde Use of SEER-Medicare data for measuring cancer surgery Med Care 40 Suppl 2002 IV-43 IV48
16. National Cancer Institute Data, Surveillance Research Program, Cancer Statistics Branch Surveillance, Epidemiology, and End Results (SEER) program http://www.seer.cancer.gov SEER (*) Stat database: IncidenceSEER 17 regs public-use, Nov 2005 sub (19732003 varying), linked to county attributes, total US 19692003 counties. Released April 2006, based on the November 2005 submission. Accessed November 2010
17. J.L. Warren, C.N. Klabunde, D. Schrag Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population Med Care 40 Suppl 2002 IV-3 IV-18
18. A.G. Fritz International classification of diseases for oncology 3rd ed. 2000 World Health Organization Geneva
19. A.L. Potosky, J.L. Warren, E.R. Riedel Measuring complications of cancer treatment using the SEER-Medicare data Med Care 40 Suppl 2002 IV-62 IV-68
20. A. Elixhauser, C. Steiner, D.R. Harris Comorbidity measures for use with administrative data Med Care 36 1998 8 27 (Pubitemid 128456396)
21. L.M. Baldwin, C.N. Klabunde, P. Green In search of the perfect comorbidity measure for use with administrative claims data: does it exist? Med Care 44 2006 745 753 (Pubitemid 44284265)
22. B. Li, D. Evans, P. Faris Risk adjustment performance of Charlson and Elixhauser comorbidities in ICD-9 and ICD-10 administrative databases BMC Health Serv Res 8 2008 12
23. H. Quan, G.A. Parsons, W.A. Ghali Validity of information on comorbidity derived from ICD-9-CCM administrative data Med Care 40 2002 675 685
24. D.A. Southern, H. Quan, W.A. Ghali Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data Med Care 42 2004 355 360
25. A. Agresti Introduction to categorical data analysis 1996 Wiley New York 182 185 187189, 201, 217, 279
26. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
27. J.P. Simons, S.C. Ng, T.P. McDade Progress for resectable pancreatic [corrected] cancer? A population-based assessment of US practices Cancer 116 2010 1681 1690
28. D.W. Crist, J.V. Sitzmann, J.L. Cameron Improved hospital morbidity, mortality, and survival after the Whipple procedure Ann Surg 206 1987 358 365 (Pubitemid 17159710)
29. J.E. Carroll, J.K. Smith, J.P. Simons Redefining mortality after pancreatic cancer resection J Gastrointest Surg 14 2010 1701 1708
30. F.R. Spitz, J.L. Abbruzzese, J.E. Lee Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas J Clin Oncol 15 1997 928 937 (Pubitemid 27106274)
31. J.D. Wayne, E.K. Abdalla, R.A. Wolff Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation Oncologist 7 2002 34 45 (Pubitemid 34151106)
32. J.M. Herman, M.J. Swartz, C.C. Hsu Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital J Clin Oncol 26 2008 3503 3510
33. Gastrointestinal Tumor Study Group Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer Gastrointestinal Tumor Study Group Cancer 59 1987 2006 2010